



California Medical Evaluators
11620 Wilshire Blvd. Suite 340
Los Angeles, CA 90025
Phone: 888.853.7944
Fax: 213.478.0550
info@calmedeval.com



Dr. Joseph W. Zaky, MD

Board Certified in Internal Medicine

Articulate, Board certified Internal Medicine with more than 15 years of clinical expertise and 1 year of medical-legal expertise. Highly specialized in Internal Medicine.

EDUCATION

- **University of California, Los Angeles, CA (2000)**
Bachelor of Science, Neuroscience
- **Mount Sinai School of Medicine, New York, NY (2004)**
Doctor of Medicine, MD
- **University of California, Los Angeles, CA (2005)**
Internship, Internal Medicine
- **University of California, Los Angeles, CA (2007)**
Residency, Internal Medicine

PROFESSIONAL EXPERIENCE

- **Los Angeles City Jails, Department of Medical Services, Physician (2006 to 2007)**
- **Southern California Kaiser Permanente, Department of Medicine, Physician (2006 to 2010)**
- **St. Mark Clinical Trails Inc., Co-Founder and VP, Principal Investigator (2010 to 2019)**
- **Home Hospice Attending Physician, Attending Physician (2015 to 2019)**
- **Anthem Blue Cross, Physician Reviewer (2015 to 2021)**
- **Mid-Valley Comprehensive Health Center and Olive View-UCLA, Physician Specialist/Director, Cardiology Exercise Treadmill Stress Lab (2007 to present)**
- **All Care to You Practice Management Group, Physician (2019 to present)**

ACADEMIC APPOINTMENTS

- David Geffen School of Medicine at UCLA, Associate Clinical Professor (2007 to present)

LICENSURE AND CERTIFICATION

- American Board of Internal Medicine
- AHA – Advanced Cardiac Life Support
- AHA – Pediatric Advanced Life Support
- AHA – Basic Cardiac Life Support
- California Board Certified Medical License

PROFESSIONAL MEMBERSHIPS

- San Fernando Valley Health Centers – Emergency Response/Assist Chairman (2010 to present)
- Society of General Internal Medicine (SGIM), Post Reviewer (2012 to 2013)

HONORS AND AWARDS

- Vaughn Physician of the Year, Mid-Valley, San Fernando, Glendale (2015)
- Champions of Change Traditional Plaque Award, County of Los Angeles Quality and Productivity Commission, 29th Annual Productivity and Quality Awards Program

RESEARCH & PUBLICATIONS

Research Trials

2011 A Phase III, Multicenter, International, Randomized, Parallel Group, Double-Blind Cardiovascular Safety Study of BI 10773 (10mg and 25mg administered orally once daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients with Increased Cardiovascular Risk. *St. Mark Clinical Trials, Sub-Investigator.*

2011 A Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects with Asthma, Phase IV. *St. Mark Clinical Trials, Sub-Investigator.*

2011 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 8-Week Study to Evaluate the Safety and Efficacy of Nebivolol and Valsartan Given as a Fixed-Dose Combination in Patients with Stage 1 or 2 Essential Hypertension. *St. Mark Clinical Trials, Sub-Investigator.*

2011 A Phase III, Randomized Clinical Trial to Study the Efficacy and Safety of the Co- Administration of Sitagliptin and Atorvastatin in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin Monotherapy. *St. Mark Clinical Trials, Sub-Investigator.*

2011 An Open-Label, 52-Week Study to Assess the Long-Term Safety of NKTR-118 in Opioid-Induced Constipation (OIC) in Patients with Non-Cancer-Related Pain. *St. Mark Clinical Trials, Sub-Investigator.*

2011 Double-Blind, Randomized, Placebo-Controlled and Active-Comparator- Controlled, Phase 2b Study to Evaluate Statin-Associated Myalgia Incidence, Lipid Profile Effect, and Safety and Tolerability Associated with PPD10558 Versus Atorvastatin in Patients with Primary Hypercholesterolemia, Fredrickson IIa or IIb, Who Have Discontinued Two or More Prior Statin Therapies Due to Statin-Associated Myalgia. *St. Mark Clinical Trials, Sub-Investigator.*

2011 A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat versus Placebo on Renal Function in Gout Subjects with Hyperuricemia and Moderate to Severe Renal Impairment. *St. Mark Clinical Trials, Sub-Investigator.*

2011 A Clinical Outcomes Study to Compare the Effect of Fluticasone/Vilanterol Inhalation Powder 100/25mcg with Placebo on Survival in Subjects with Moderate Chronic Obstructive Pulmonary Disease (COPD) and a History of or at Increased Risk for Cardiovascular Disease. *St. Mark Clinical Trials, Sub-Investigator.*

2012 A 6-Month Safety and Benefit Study of Inhaled Fluticasone Propionate/Salmeterol Combination versus Inhaled Fluticasone Propionate in the Treatment of 6,200 Pediatric Subjects 4-11 Years Old with Persistent Asthma, Phase IV. *St. Mark Clinical Trials, Sub-Investigator.*

2012 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Patients with Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC). *St. Mark Clinical Trials, Principal Investigator.*

2012 A Phase III, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Daily Oral Administration of BI 10773 25mg/Linagliptin 5mg and BI 10773 10mg/Linagliptin 5mg Fixed-Dose Combination Tablets Compared with the Individual Components (BI 10773 25mg, BI 10773 10mg, Linagliptin 5mg) for 52 Weeks in Treatment Naïve and Metformin-Treated Patients with Type 2 Diabetes Mellitus with Insufficient Glycemic Control. *St. Mark Clinical Trials, Sub-Investigator.*

2012 A Phase III, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects with Gout Who Have Had an Inadequate Hypouricemic Response to Standard of Care Allopurinol. *St. Mark Clinical Trials, Principal Investigator.*

2012 A Phase III, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects with Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor. *St. Mark Clinical Trials, Principal Investigator.*

2012 A Phase III, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Febuxostat Compared to Febuxostat Alone at Lowering Serum Uric Acid and Resolving Tophi in Subjects with Tophaceous Gout. *St. Mark Clinical Trials, Principal Investigator.*

2013 A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of MK-3102 to Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy. *St. Mark Clinical Trials, Principal Investigator.*

2013 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Long-Term Safety and Tolerability of CB-5945 for the Treatment of Opioid-Induced Constipation in Adults Taking Opioid Therapy for Chronic Non-Cancer-Related Pain. *St. Mark Clinical Trials, Principal Investigator.*

2013 A Long-Term, Open-Label Extension Study for Subjects Completing a Phase III Efficacy and Safety Study of Lesinurad Monotherapy in Subjects with Gout. *St. Mark Clinical Trials, Principal Investigator.*

2015 A Phase III, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Nebulized TD-4208 in Subjects with Chronic Obstructive Pulmonary Disease. *St. Mark Clinical Trials, Principal Investigator.*

2015 A Phase III, 52-Week, Randomized, Active-Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized TD-4208 in Subjects with Chronic Obstructive Pulmonary Disease. *St. Mark Clinical Trials, Principal Investigator.*

2016 A Randomized, Double-Blind, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations over a 52-Week Treatment Period in Subjects with Moderate to Very Severe COPD. *St. Mark Clinical Trials, Principal Investigator.*

Research Experience

UCLA Department of Psychology (Los Angeles, CA) Aug. 1997 to June 1998

Advisor: Bernard Balleine, PhD

Performed experiments studying instrumental conditioning and the role of the hippocampus on behavior and memory. Assisted in surgical procedures for hippocampal lesions.

UCLA Department of Emergency Medicine (Los Angeles, CA) Jan. 1998 to June 1999

Advisor: Larry Baraff MD, Frederick Beddingfield MD

Director and Administrator of the Medical Screening Study. Developed a protocol that allowed triage nurses to accurately assess all situations presented through the emergency room. The protocol assessed whether each patient was emergent, urgent, or non-urgent and facilitated emergency care providers and consumers by accurately prioritizing cases.

UCLA Department of Surgery (Los Angeles, CA) June 1998 to Aug. 2000

Advisor: Douglas Farmer MD, Farin Amersi MD

Studied the effects of P-selectin glycoprotein ligand-1 and other novel therapies in reducing ischemia reperfusion injury in fatty livers using an ex-vivo liver perfusion apparatus. The study hoped to increase the amount of available donor livers by at least 20%.

Cedars-Sinai Medical Center Dept. of Non-Invasive Cardiology (Los Angeles, CA) June 2001 to Aug. 2003

Advisor: Tasneem Naqvi MD

Assisted in the clinical trials of a new contrast medium that would allow physicians to better assess heart wall viability after myocardial infarctions. Case studies on various topics, including new onset systolic murmurs and their association with aortic dissections.

Research Papers

1. Amersi F, Buelow R, Kato H, Ke B, Coito A, Shen XD, Zhao D, **Zaky J**, Melinek J, Lassman C, Kolls J, Alam J, Ritter T, Volk HD, Farmer D, Ghobrial R, Busuttill R and Kupiec-Weglinski J. Upregulation of Heme Oxygenase-1 Protects Genetically Fat Zucker Rat Livers from Ischemia/Reperfusion Injury. *Journal of Clinical Investigation*. 1999; 104:1631-1639.

2. Amersi F, Dulkanchainun T, Nelson S, Farmer D, Kato H, **Zaky J**, Melinek J, Shaw G, Kupiec-Weglinski J, Horwitz L, Horwitz M, and Busuttill R. A Novel Iron Chelator in Combination with a P-Selectin Antagonist Prevents Ischemia/Reperfusion Injury in a Rat Liver Model. *Transplantation*. 2001; 71:112-118.

3. Si MS, Amersi F, Golish S, Ortiz J, **Zaky J**, Finklestein D, Busuttil R, Imagawa D. Prevalence of Metastases in Hepatocellular Carcinoma: Risk Factors and Impact on Survival. *Journal of the American College of Surgeons*. 2003; 69(10): 879-885.
4. Naqvi T, **Zaky J**, Raissi S. Transesophageal Echocardiographic Evaluation of Perioperative Systolic Murmur in Aortic Pathology. *Reviews in Cardiovascular Medicine*. 2003; 4:112-116.
5. Naqvi T, **Zaky J**. Electrical Dissociation within Left Atrial Appendage Diagnosed by Doppler Echocardiography. *Journal of the American Society of Echocardiography*. 2004; 10:1077-1079.
6. **Zaky J**, Caraang C, Yu R, El-Bialy A. Elevated Troponins and the Churg-Strauss Syndrome: A Case Report. *Journal of Cardiovascular Pharmacology and Therapeutics*. 2005; 10(2):131-136.